DOI QR코드

DOI QR Code

Associations between an MDM2 gene polymorphism and ulcerative colitis by ARMS-PCR

  • Received : 2020.02.11
  • Accepted : 2020.02.26
  • Published : 2020.03.31

Abstract

Ulcerative colitis is a form of inflammatory bowel disease characterized by chronic inflammation of the colon and rectum. The abnormal lesions in the digestive system caused by ulcerative colitis and intermittent colitis are of major clinical importance. MDM2 is a phospho-protein that functions as a ubiquitin ligase for p53. Recently, a T>G substitution in the promoter of the MDM2 gene (rs309) has been identified. In this case-control study, 174 ulcerative colitis biopsy samples and 82 control samples were collected from colonoscopy centers, hospitals, and clinics in Mazandaran and Gilan Provinces in Iran from October 2014 to May 2015. This MDM2 polymorphism was investigated in DNA samples (extracted from biopsy samples) by amplification-refractory mutation system polymerase chain reaction. The mean age of patients with ulcerative colitis was 46.5 years (range, 28 to 69 years) and that of control individuals was 45.3 years (range, 26 to 71 years). Seventy-eight patients (44.82%) were men and 96 (55.18%) were women. The distribution of the TT, TG, and GG genotypes was 17.93%, 27.59%, and 34.48%, respectively, in the ulcerative colitis patients and 31.70%, 24.40%, and 43.90%, respectively, in the control individuals (odds ratio of GG for ulcerative colitis, 7.142; 95% confidence interval, 2.400 to 9.542; p = 0.001). It was found that a single-nucleotide polymorphism at rs309 in the MDM2 gene was associated with ulcerative colitis. A direct relationship was found between age and ulcerative colitis, while no relationship was found with sex. This finding is of note because the occurrence of intestinal inflammation and subsequent ulcers can precede the development of cancer.

Keywords

References

  1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-429. https://doi.org/10.1056/NEJMra020831
  2. Colombel JF, Tamboli C, Hugot JP. Clinical genetics of inflammatory bowel diseases: genetic epidemiology, genotype-phenotype correlations and pharmacogenetics. In: Kirsner's Inflammatory Bowel Diseases, 6th ed. (Sartor RB, Sandborn WJ, eds.). New Delhi: Elsevier, 2005. pp. 263-279.
  3. Cucchiara S, Stronati L. Ulcerative colitis: Paediatric ulcerative colitis: can we predict proctocolectomy? Nat Rev Gastroenterol Hepatol 2012;9:494-495. https://doi.org/10.1038/nrgastro.2012.153
  4. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380:1606-1619. https://doi.org/10.1016/S0140-6736(12)60150-0
  5. Mashako MN, Cezard JP, Navarro J, Mougenot JF, Sonsino E, Gargouri A, et al. Crohn's disease lesions in the upper gastrointestinal tract: correlation between clinical, radiological, endoscopic, and histological features in adolescents and children. J Pediatr Gastroenterol Nutr 1989;8:442-446. https://doi.org/10.1097/00005176-198905000-00004
  6. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med 2011;365:1713-1725. https://doi.org/10.1056/NEJMra1102942
  7. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-1517. https://doi.org/10.1053/j.gastro.2004.01.063
  8. Garcia Rodriguez LA, Gonzalez-Perez A, Johansson S, Wallander MA. Risk factors for inflammatory bowel disease in the general population. Aliment Pharmacol Ther 2005;22:309-315. https://doi.org/10.1111/j.1365-2036.2005.02564.x
  9. Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett 2006;240:261-267. https://doi.org/10.1016/j.canlet.2005.09.019
  10. Lundgren K, Montes de Oca Luna R, McNeill YB, Emerick EP, Spencer B, Barfield CR, et al. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev 1997;11:714-725. https://doi.org/10.1101/gad.11.6.714
  11. Campbell IG, Eccles DM, Choong DY. No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 2006;240:195-197. https://doi.org/10.1016/j.canlet.2005.09.003
  12. Quesnel B, Preudhomme C, Fournier J, Fenaux P, Peyrat JP. MDM2 gene amplification in human breast cancer. Eur J Cancer 1994;30A:982-984.
  13. Sotamaa K, Liyanarachchi S, Mecklin JP, Jarvinen H, Aaltonen LA, Peltomaki P, et al. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res 2005;11:6840-6844. https://doi.org/10.1158/1078-0432.CCR-05-1139
  14. Enokida Y, Shimizu K, Kakegawa S, Atsumi J, Takase Y, Miyamae Y, et al. Single-nucleotide polymorphism (c.309T>G) in the MDM2 gene and lung cancer risk. Biomed Rep 2014;2:719-724. https://doi.org/10.3892/br.2014.305
  15. Hou H, Sun D, Zhang X. The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors. Cancer Cell Int 2019;19:216. https://doi.org/10.1186/s12935-019-0937-4